Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    pipeline-prospector-insert-v1
    X

    Find Novel Oncology Drugs in Clinical Development in NETHERLANDS

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type

              Companies

              Lava Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              NETHERLANDS Netherlands

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Immuno-Oncology 360

              Participation Not Confirmed

              Update your events

              ProBioGen, Lava Therapeutics Sign Cell Line Mfg. Pact

              Contact the Supplier

              Lead Product(s): Vγ9Vδ2 T cells based antibodies,V?9V?2 T cells based antibodies

              Therapeutic Area: Oncology

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: ProBioGen AG

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement January 14, 2020

              Details:

              Under the agreement and using its CHO.RiGHT™ expression platform, ProBioGen will conduct cell line development of a γδ T-cell engaging bispecific antibody format.

              Synaffix

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              NETHERLANDS Netherlands

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Immuno-Oncology 360

              Participation Not Confirmed

              Update your events

              Synaffix announces expansion of license agreement with Shanghai Miracogen Inc. to a second ADC candidate

              Contact the Supplier

              Lead Product(s): Antibody drug conjugate linker

              Therapeutic Area: Oncology

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Shanghai Miracogen

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 07, 2020

              Details:

              Miracogen has been granted non-exclusive rights to Synaffix’s proprietary GlycoConnect™ and HydraSpace™ ADC technologies for use in this second clinical candidate.

              PharmaCompass__DigitalAd